619334-36-0

Usage

Uses

Used in Organic Synthesis:
6-THIEN-2-YLNICOTINONITRILE 97+%3-CYANO-6-THIEN-2-YLPIRIDINE is used as a building block for the synthesis of heterocyclic compounds, which are essential in the development of pharmaceuticals and other organic compounds.
Used in Pharmaceutical Research:
6-THIEN-2-YLNICOTINONITRILE 97+%3-CYANO-6-THIEN-2-YLPIRIDINE is used as an intermediate in pharmaceutical research for the development of new drugs and biologically active compounds, due to their unique chemical structures and properties.
Used in Drug Development:
6-THIEN-2-YLNICOTINONITRILE 97+%3-CYANO-6-THIEN-2-YLPIRIDINE is used as a key component in the design and synthesis of new drug candidates, contributing to the advancement of medicinal chemistry and the discovery of novel therapeutic agents.
Used in the Pharmaceutical Industry:
6-THIEN-2-YLNICOTINONITRILE 97+%3-CYANO-6-THIEN-2-YLPIRIDINE is used as a raw material for the production of pharmaceuticals, given their potential to form the basis of new drug molecules with therapeutic applications.
Used in Biological Research:
6-THIEN-2-YLNICOTINONITRILE 97+%3-CYANO-6-THIEN-2-YLPIRIDINE is used as a research tool in biological studies to understand the interactions of these compounds with biological systems, which can lead to insights into their potential applications in medicine and other fields.

InChI:InChI=1/C10H6N2S/c11-6-8-3-4-9(12-7-8)10-2-1-5-13-10/h1-5,7H

Upstream product

• 33252-28-7 6-chloronicotinonitrile 
• 54663-78-4 tributyl(thien-2-yl)stannane 
• 139585-70-9 2-bromo-5-cyanopyridine 
• 193978-23-3 2-thiopheneboronic acid pinacol ester 

Downstream Products

• 619334-40-6 N-hydroxy-6-{5-[4-(N-hydroxycarbamimidoyl)-phenyl]-thiophen-2-yl}-nicotinamidine 
• 619334-38-2 6-[5-(4-cyano-phenyl)-thiophen-2-yl]-nicotinonitrile 

Relevant academic research and scientific papers

Heterocyclic Diamidine DNA Ligands as HOXA9 Transcription Factor Inhibitors: Design, Molecular Evaluation, and Cellular Consequences in a HOXA9-Dependant Leukemia Cell Model

Most transcription factors were for a long time considered as undruggable targets because of the absence of binding pockets for direct targeting. HOXA9, implicated in acute myeloid leukemia, is one of them. To date, only indirect targeting of HOXA9 expres

SUSTITUTED ( HETEROARYLMETHYL ) THIOHYDANTOINS AS ANTICANCER DRUGS

The invention relates to substituted (heteroarylmethyl) thiohydantoin compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, and their use for the preparation of medicaments for the treatment and/or prophylaxis of disorders, in particular of prostate cancer.

Synthesis and Antiprotozoal Activity of Aza-Analogues of Furamidine

6-[5-(4-Amidinophenyl)furan-2-yl]nicotinamidine (8a) was synthesized from 6-[5-(4-cyanophenyl)furan-2-yl]nicotinonitrile (4a), through the bis-O-acetoxyamidoxime followed by hydrogenation. Compound 4a was prepared via selective bromination of 6-(furan-2-yl)nicotinonitrile (2a) with N-bromosuccinimide, followed by Suzuki coupling with 4-cyanophenylboronic acid. In a similar way, diamidines 8b and 8c were prepared from the dicyano derivatives 4c and 4d, respectively. N-Methoxy-6-[5-[4-(N-methoxyamidino)phenyl]-furan-2-yl}-nicotinamidine (6a) was prepared via methylation of the respective diamidoxime 5a with dimethylsulfate. Prodrugs 6b and 6c were also prepared by methylation of the respective diamidoximes 5b and 5d. The symmetrical diamidines 14a,b were synthesized through the corresponding bis-O-acetoxyamidoxime followed by hydrogenation. The key compounds 11a,b were conveniently obtained by Stille coupling between 2,5-bis(tri-n-butylstannyl)furan and the corresponding heteroaryl halides. These compounds have been evaluated in vitro for activity against Trypanosoma b. rhodesiense (T. b. r.) and P. falciparum (P. f.). The diamidines 8a, 8c, and 14b gave IC50 values versus T. b. r. of less than 10 nM. Against P. f. 8a, 8b, and 14b exhibited IC50 values less than 10 nM. In an in vivo mouse model for T. b. r. four compounds 6a, 6c, 6d, and 8a were curative. Compound 6a produced cures at an oral dosage of 5 mg/kg.